Purpose: The aim of this study was to determine if imaging with 89 Zrtrastuzumab, a human epidermal growth factor receptor 2 (HER2)-targeting PET tracer, can detect HER2-positive metastases in patients with HER2-negative primary breast cancer. Methods: As part of an institutional review board-approved, prospective clinical trial of 89 Zr-trastuzumab PET/CT (ClinicalTrials.gov identifier NCT02286843), a second group of 11 patients with HER2-negative primary breast cancer and known metastatic disease were recruited. Patients with confirmed HER2-negative primary breast cancer underwent Zr-trastuzumab-avid foci had biopsy demonstrating a metastasis that was HER2-negative and were considered false-positive 89 Zr-trastuzumab PET foci. Combined with a published report of the first 9 patients, there have been a total of 20 HER2-negative primary breast cancer patients, with 3 patients (15%) having pathologically confirmed HER2-positive distant metastases and 6 (30%) with suspicious 89 Zr-trastuzumab-avid foci that were HER2-negative on pathology, which were thus considered false-positive 1 Classification of a breast malignancy as HER2-positive or HER2-negative is an essential component of clinical care, as patients with HER2-positive breast cancer receive specific targeted HER2 therapies that reduce the risk of death, whereas patients with HER2-negative breast cancer do not.
A pproximately 20% of invasive ductal breast malignancies are classified as human epidermal growth factor receptor 2 (HER2)-positive because of overexpression of the HER2 protein on the surface of tumor cells or gene amplification. 1 Classification of a breast malignancy as HER2-positive or HER2-negative is an essential component of clinical care, as patients with HER2-positive breast cancer receive specific targeted HER2 therapies that reduce the risk of death, whereas patients with HER2-negative breast cancer do not. 2, 3 An important question is whether HER2 status could be heterogeneous between sites of malignancy in a single patient. If heterogeneity exists, then classification of HER2 status from 1 biopsy may inaccurately describe the extent of disease in a patient with the potential to respond to HER2-targeted therapy. Indeed, heterogeneity of tumors both within and across lesions in a single patient is increasingly being recognized. 4 Investigators have identified patients with HER2-positive primary malignancies in which metastases have lost HER2 positivity. 5 Potentially more clinically significant, investigators have identified patients with HER2-negative primary malignancies in which metastases have acquired HER2 positivity. These patients may benefit from HER2-targeted therapies that they are not receiving because they are not considered to have HER2-positive disease.
It is currently unclear how to best identify patients who have malignancy with heterogeneous HER2 expression. Identification by biopsy would be difficult because only small samples of tissue from a limited number of lesions are normally sampled. We hypothesized that HER2 heterogeneity may be identified by imaging with a HER2-targeting radiotracer and designed a prospective clinical trial to evaluate HER2 heterogeneity with 89 Zr-trastuzumab PET/CT, which allows for visualization of HER2-positive malignancy. 6 We published the initial results from the first 9 patients and demonstrated the ability of 89 Zr-trastuzumab PET/CT to identify HER2-positive metastases in patients with HER2-negative primary breast malignancy. 7 We present the results of the second group of patients, comprising 11 patients.
PATIENTS AND METHODS

Patients
A single-center, prospective, institutional review board-approved protocol (ClinicalTrials.gov identifier NCT02286843) was performed. Patients receiving treatment for metastatic HER2-negative primary breast cancer were identified as potential candidates. Inclusion criteria were as follows: (1) biopsy-proven HER2-negative primary malignancy; (2) biopsy-proven metastatic disease; (3) foci of demonstrable metastases on imaging modalities within 6 weeks of enrollment; (4) women 18 or older; and (5) Eastern Cooperative Oncology Group performance score of 0 to 2. Exclusion criteria were as follows: (1) creatinine more than 2 times the upper limit of normal; (2) aspartate aminotransferase/alanine aminotransferase more than 2 times the upper limit of normal; (3) life expectancy of less than 3 months; (4) pregnancy or lactation; and (5) inability to undergo PET/CT scanning because of weight limits. All patients enrolled in the protocol provided written informed consent.
Confirmation of HER2 Status of the Primary Breast Malignancy
The primary breast cancer tissue sample for each patient was retested for HER2 status to ensure proper classification as HER2-negative. Human epidermal growth factor receptor 2 protein overexpression was evaluated by immunohistochemistry (IHC) using a US Food and Drug Administration (FDA)-approved monoclonal antibody (clone 4B5; Ventana, Tucson, AZ) directed against the internal domain of the c-erbB-2 oncoprotein (HER2). The IHC results were categorized as follows: 0, 1+ = negative result, 2+ = equivocal result, and 3+ = positive result, according to the published American Society of Clinical Oncology (ASCO) guidelines 8 ( Zr-trastuzumab was produced under Good Manufacturing Practice conditions using previously described methodology. 9 The final drug product for human use was manufactured, and quality control tested prior to being released for patient administration to ensure that it conformed to the established acceptance specifications for appearance, pH, endotoxin content, sterilizing filter integrity, radiochemical purity, and radionuclidic identity. Sterility and immunoreactivity determinations were performed after release.
Patients were intravenously administered 185 MBq ± 10% of 89 Zr-trastuzumab over 5 minutes. Radiolabeled 89 Zr-trastuzumab was brought up to a final mass dose of 50 mg by adding nonradiolabeled trastuzumab at the end of the production because this has been shown to help optimize tumor targeting. 6 The final mass dose of 50 mg was provided by the Radiochemistry and Molecular Imaging Probe Core at Memorial Sloan Kettering Cancer Center to the clinic for patient administration. Five or 6 days following 89 Zr-trastuzumab administration, patients underwent PET/CT from the midskull to midthigh on a dedicated research GE Discovery PET/CT 710 scanner (GE Healthcare, Chicago, IL), with an 80-mA CT component for attenuation correction and lesion localization. PET/CT images were reconstructed using iterative reconstruction and displayed in multiplanar reconstructions. Zrtrastuzumab uptake was expected in the blood pool, liver, gallbladder, bowel, and kidney. Radiotracer uptake in areas that are not physiologic were graded both qualitatively and semiquantitatively. For qualitative scoring, lesions were scored as suspicious or not suspicious. Only those foci qualitatively scored as suspicious by both readers were considered suspicious foci. Semiquantitative analysis of tracer uptake was performed by recording the SUVmax of suspicious lesions. Three-dimensional volumes of interest were placed Patients 11 to 20, all with primary invasive ductal breast cancer, are reported here. The first 9 patients were reported in the initial results of the trial. 7 Clinical Nuclear Medicine • Volume 42, Number 12, December 2017 HER2 + PET in HER2 − Primary BC in these areas, and tracer uptake was quantified using SUV, calculated as decay-corrected mean region of interest activity (μCi/mL)/ (injected dose (μCi)/body weight (g)).
Biopsy and Pathologic Evaluation of Suspicious 89
Zr-Trastuzumab Foci
Image-guided biopsy was selected in concert with an experienced oncologic interventional radiologist to minimize risks to the patient while obtaining high-quality samples. Biopsy specimens were evaluated by board-certified breast pathology specialists. The IHC results were categorized according to published ASCO guidelines, 8 as discussed previously and in Table 1 . Carcinomas with 3+ IHC staining or 2+ IHC staining and concurrent positive HER2 FISH were classified as HER2-positive metastases.
RESULTS
Patient Characteristics
Between December 2015 and May 2016, a second group of 11 women with HER2-negative primary invasive ductal breast cancer completed the study protocol. These were designated patient numbers 10 to 20, following the first 9 patients described in the initial publication. 7 Patient characteristics and study results are summarized in Table 2 .
Sites of Distant Metastases at Time of Protocol Enrollment
All 11 patients had at least 1 site of metastatic disease at the time of protocol enrollment. The most common sites of distant metastases were bone (n = 7), nodal (n = 7), and liver (n = 7), followed by lung (n = 2), pleural (n = 1), and chest wall (n = 1). Nine of the 11 patients had multiple organ system metastatic involvement.
Confirmation of HER2 Status of the Primary Breast Malignancy
On IHC retesting of the patients' archived primary breast cancer specimens, all 11 patients had confirmed HER2-negative primary malignancies according to published ASCO guidelines. 8 Three patients had HER2 IHC scores of 0, whereas 7 had HER2 IHC scores of 1+, and 1 had a HER2 IHC score of 2+ with a FISH of 1.4. (Fig. 2) . A lung lesion had been pathologically confirmed as metastasis. (Fig. 3) . Bone and liver lesions had been pathologically confirmed as metastases. 
DISCUSSION
This study describes a second group of 11 patients in a prospective clinical trial of HER2-targeted imaging with 89 Zrtrastuzumab PET/CT to evaluate for unsuspected HER2-positive metastases in patients with HER2-negative primary breast cancer. It demonstrates that in a small subset of patients with HER2-negative primary breast cancer HER2-targeted imaging can detect previously unsuspected HER2-positive disease.
Between the current group of 11 patients and a previously published initial group of 9 patients, 7 a completed cohort of 20 patients with HER2-negative primary breast cancer have now been evaluated. In total, 3 (15%) of 20 patients were demonstrated to have biopsy-proven unsuspected HER2-positive metastases. In another 6 (30%) of 20 patients, suspicious 89 Zr-trastuzumab-avid foci resulted in biopsies with HER2-negative pathology, which are being conservatively considered false-positive 89 Zr-trastuzumabavid foci.
While medical imaging of oncology patients has traditionally been used for the detection of tumors, staging, and evaluation of treatment response, this study suggests that targeted medical imaging may be able to help select patients for targeted systemic therapies. More than 900,000 women are living with metastatic breast cancer, with more than 50,000 diagnosed each year. 10 Eighty percent of these women have HER2-negative primary malignancies.
If 15% of patients with metastatic HER2-negative primary breast cancer could be found to harbor HER2-positive metastases, this would represent a current population of 135,000 women. Thus, targeted HER2 imaging has the potential to play a clinically valuable role in identifying patients who may benefit from HER2-targeted therapies.
A limitation of this approach is the currently high level of presumably false-positive suspicious 89 Zr-trastuzumab-avid foci. This leads to unneeded workup and biopsies. The reason for these false-positive foci is unclear. One possibility is pathologic sampling or processing errors. For example, decalcification of osseous lesions may decrease the intensity of HER2 IHC staining, resulting in a false-negative pathologic result. 11 If a lesion exhibits heterogeneity of HER2 expression, it is possible that in any one biopsy the HER2-positive malignancy was undersampled. Although this could result in erroneous pathologic analysis, given the high number of false-positives, it is likely that at least some represent nonspecific 89 Zr-trastuzumab uptake in HER2-negative lesions. Another possible explanation is free 89 Zr being released from its chelator during the long 5-day uptake period. When loosely chelated, 89 Zr is known to be a bone seeker. 12 Indeed, evidence suggests that when 89 Zr is chelated to antibodies with desferrioxamine radioactivity accumulates in the bone. 13 Thus, nonspecific binding of potentially free 89 Zr at sites of osseous turnover associated with bone metastases could result in false-positive osseous foci. Another possible explanation for presumed false-positive 89 Zr-trastuzumab-avid foci could be related to in vivo HER2 internalization rates or affinity differences that would not necessarily be reflected by IHC or FISH.
14 More specific HER2-targeting radiotracers will need to Zr-pertuzumab, which demonstrated HER2 specificity in animal models. 15 Human epidermal growth factor receptor 2-negative patients have been reported to respond to trastuzumab therapy. It would be of interest to evaluate if patients with positive 89 Zr-trastuzumab scans but negative HER2 status by conventional criteria respond to trastuzumab. This would raise the potential of using 89 Zrtrastuzumab as a predictive biomarker 16 and selecting patients for HER2-target therapy based on imaging.
It is interesting to note that the intensity of 89 Zr-trastuzumab avidity did not discriminate between true-positive and false-positive lesions for HER2 expression. The most 89 Zr-trastuzumab-avid lesion in the study was a hepatic lesion (patient 20; SUV, 15.7), which had a HER2-negative pathology. Likewise, a substantially less 89 Zrtrastuzumab-avid lesion (patient 14; SUV, 6.9) had HER2-positive pathology and was a true-positive.
Another interesting issue was that even when a 89
Zrtrastuzumab-avid focus was considered a false-positive, there could be noticeable heterogeneity in HER2 expression between the primary malignancy and the avid metastasis. For example, patient 11 had a primary malignancy with an IHC of 0. The 89 Zrtrastuzumab-avid osseous metastasis that was biopsied had an IHC of 2+ and FISH of 1.6. While IHC 2+/FISH 1.6 is considered HER2-negative by ASCO guidelines, it still represents a change from the primary malignancy. The value of 89 Zr-trastuzumab PET/ CT for evaluating this type of heterogeneity needs further evaluation.
The strength of this study is its design as a prospective clinical trial, whereas its weakness is still the small sample size. Ethical standards and logistical obstacles prevent biopsy of all 89 Zrtrastuzumab foci; thus, pathology is classified on the basis of a limited number of biopsies. Likewise, ethical standards prevent biopsy confirmation of HER2-negative status of metastases in patients without suspicious foci on 89 Zr-trastuzumab imaging.
In conclusion, 89 Zr-trastuzumab PET/CT can be used to detect unsuspected HER2-positive metastases in a subset of patients with HER2-negative primary breast cancer. This demonstrates that targeted imaging can identify patients amenable to targeted therapies. Presumed false-positive results currently limit the translation of these techniques, but there is great potential for more specific methodology to have substantial clinical value in the future.
